Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.4593
-0.0305-6.23%
Volume:677.87K
Turnover:323.30K
Market Cap:28.46M
PE:-0.48
High:0.5000
Open:0.5000
Low:0.4518
Close:0.4898
Loading ...

Cognition Therapeutics announces results in Phase 2 study of CT1812

TIPRANKS
·
18 Dec 2024

Cognition Therapeutics Inc: Expediting Plans to Advance Ct1812 Into Late-Stage Trials

THOMSON REUTERS
·
18 Dec 2024

Cognition Therapeutics Inc - Study Met Primary Endpoint of Safety and Tolerability

THOMSON REUTERS
·
18 Dec 2024

Cognition Therapeutics Announces Positive Results in Phase 2 Study of Ct1812 in Dementia With Lewy Bodies

THOMSON REUTERS
·
18 Dec 2024

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

GlobeNewswire
·
18 Dec 2024

We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate

Simply Wall St.
·
13 Dec 2024

Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
28 Nov 2024

Positive Clinical Trial Developments and Financial Position Drive Buy Rating for Cognition Therapeutics

TIPRANKS
·
27 Nov 2024

BRIEF-Cognition Therapeutics Announces All Participants Have Completed Their Final Visits

Reuters
·
26 Nov 2024

Cognition announces all participants completed final visit in SHIMMER study

TIPRANKS
·
26 Nov 2024

Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysis

TipRanks
·
26 Nov 2024

Cognition Therapeutics Announces All Participants Have Completed Their Final Visits in the Phase 2 Shimmer Study of Ct1812 in Dementia With Lewy Bodies

THOMSON REUTERS
·
26 Nov 2024

Cognition Therapeutics Inc -Topline Results in Second Dementia Indication Expected to Be Reported in December 2024

THOMSON REUTERS
·
26 Nov 2024

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

GlobeNewswire
·
26 Nov 2024

BRIEF-Cognition Therapeutics’ Analysis Correlates Biomarker Changes With Cognitive Benefit In Alzheimer’S Population

Reuters
·
25 Nov 2024

Cognition Therapeutics’ Analysis Correlates Biomarker Changes With Cognitive Benefit in Alzheimer’s Population

THOMSON REUTERS
·
25 Nov 2024